---
layout: default
title: Ramucirumab
parent: 僅模型預測 (L5)
nav_order: 55
evidence_level: L5
indication_count: 10
---

# Ramucirumab
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Ramucirumab: Drug Repurposing Assessment — Insufficient Data for Full Evaluation

## One-Sentence Summary

Ramucirumab is a fully human IgG1 monoclonal antibody targeting VEGFR-2, developed as an antineoplastic agent for gastric/GEJ adenocarcinoma, NSCLC, and colorectal cancer.
The current Evidence Pack contains **no TxGNN-predicted new indications**, and Germany market authorization records were not retrieved (0 licenses on file).
A complete repurposing evaluation cannot be performed at this stage; this report documents available findings and the data gaps that must be resolved before proceeding.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not specified in Evidence Pack |
| Predicted New Indication | None — TxGNN predictions not available |
| TxGNN Prediction Score | Not available |
| Evidence Level | Not assessable |
| Germany Market Status | Not marketed (0 authorizations on file) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Mechanism of Action

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on known pharmacological information, Ramucirumab is a fully human IgG1 monoclonal antibody that selectively binds to the extracellular domain of VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2), blocking the binding of VEGF-A, VEGF-C, and VEGF-D ligands and their downstream pro-angiogenic signaling cascades.

Its antitumour efficacy in gastric and gastroesophageal junction adenocarcinoma has been established in pivotal Phase 3 trials (REGARD, RAINBOW). By targeting tumour vasculature rather than cancer cells directly, the mechanism is theoretically applicable to any solid tumour with significant VEGFR-2-dependent angiogenesis — a rationale that has already supported approval extensions to NSCLC, colorectal cancer, and hepatocellular carcinoma in multiple jurisdictions.

Once TxGNN prediction data becomes available, mechanism-disease alignment can be formally evaluated.

---

## Cytotoxicity

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Targeted therapy — Anti-VEGFR2 monoclonal antibody (antiangiogenic) |
| Myelosuppression Risk | Low to moderate (neutropenia has been reported; considerably less severe than conventional cytotoxic chemotherapy) |
| Emetogenicity Classification | Low |
| Monitoring Items | Blood pressure (hypertension is a class effect of anti-VEGF agents), urinalysis for proteinuria, CBC with differential, hepatic function, wound healing status |
| Handling Protection | Standard biologic handling protocols apply; not classified as a conventional cytotoxic agent requiring cytotoxic spill kits or HEPA-protected preparation areas |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is missing all three prerequisites for a repurposing evaluation — TxGNN prediction output, safety/contraindication data, and Germany market authorization records — making it impossible to assess either therapeutic opportunity or risk profile at this time.

**To proceed, the following is needed:**

- **TxGNN predictions** (`predicted_indications`) must be generated for Ramucirumab before any indication assessment can begin
- **Package insert warnings and contraindications** — TFDA PDF parsing was logged as successful (query 4) but no data was returned; this must be resolved
- **Drug interaction data** — DDI query returned `not_found`; a broader database search (e.g., DrugBank, Lexicomp) is recommended
- **Germany BfArM/EMA authorization check** — Ramucirumab may hold EMA marketing authorisation that was not captured in this query; a direct EMA product database lookup is advised to confirm actual market status before classifying as "not marketed"
- **MOA data from DrugBank** — DrugBank query returned 1 result (query 3) but `original_moa` was not populated; the DrugBank record should be re-parsed to extract mechanism, categories, and toxicity fields
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

